Zoledronic Acid Injection
Product Images NDC 68001-611

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zoledronic Acid (NDC 68001-611). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zolderonic Acid Bag Label (Bag Label)

Label for Zoledronic Acid Injection 5 mg per 100 mL sterile solution for intravenous infusion by BluePoint Laboratories. The single-dose 100 mL bag contains 5 mg zoledronic acid, with administration instructions and storage conditions included. Manufactured by Gland Pharma Limited in India.*

FDA Label Image

Zoledronic Acid Carton (Zoledronic Acid Injection Carton Rev 112023)

Box label for Zoledronic Acid Injection 5 mg per 100 mL (0.05 mg per mL) sterile solution for intravenous infusion. The label includes usage warnings, storage instructions, and administration guidance. It is labeled as Rx only and manufactured by BluePoint Laboratories. The packaging also indicates the product is a single-dose 100 mL bag.*

FDA Label Image

Pouch Label (Zoledronic Acid Injection Pouch Label Rev 112023)

Label for Zoledronic Acid Injection 5 mg per 100 mL (0.05 mg per mL) sterile solution in a 100 mL vial. The label includes dosing and administration instructions, storage conditions, and manufacturer information. It is labeled for Rx only and shows the NDC 68001-611-33. The product is labeled by BluePoint Laboratories for intravenous use.*

FDA Label Image

Image01 (Image01)

Chemical structure diagram of zoledronic acid, displaying its molecular framework with nitrogen and phosphorus atoms clearly depicted.*

FDA Label Image

Image02 (Image02)

A line chart comparing the time to first hip fracture over 36 months between placebo and Zoledronic acid groups. The chart shows cumulative incidence on the y-axis and time in months on the x-axis. The Zoledronic acid group has a lower incidence than placebo, with a reported stratified log-rank test p-value of 0.0024.*

FDA Label Image

Image03 (Image03)

This image contains two bar charts comparing Zoledronic acid and Risedronate over time. The left chart shows therapeutic response rates at different days, indicating higher response rates for Zoledronic acid. The right chart shows serum alkaline phosphatase (SAP) normalization percentages over the same time points, with Zoledronic acid demonstrating greater SAP normalization. Statistically significant differences are noted at various time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.